MBCProject_6246_T1_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UNFOLDED_PROTEIN_RESPONSE+0.300
- GLYCOLYSIS+0.270
- ANGIOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- NOTCH_SIGNALING+0.240
- MYC_TARGETS_V1+0.200
- PROTEIN_SECRETION+0.200
- APICAL_JUNCTION+0.190
- COAGULATION+0.180
- ESTROGEN_RESPONSE_EARLY+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- IL6_JAK_STAT3_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.340
- INFLAMMATORY_RESPONSE-0.310
- IL2_STAT5_SIGNALING-0.280
- COMPLEMENT-0.240
- APOPTOSIS-0.230
- HEME_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932825 | — | — | 0.779 |
| 2 | TCGA-UF-A7JK-01A-11R-A34R-07 | — | — | 0.769 |
| 3 | MNG503 | — | — | 0.744 |
| 4 | TCGA-CV-6945-01A-11R-1915-07 | — | — | 0.724 |
| 5 | SRR12202487 | — | — | 0.714 |
| 6 | MBCProject_3896_T4_RNA | — | C | 0.712 |
| 7 | MBCProject_0063_T1_RNA | — | C | 0.708 |
| 8 | 0177d00d-7d3f-43c8-8d0f-e6333e73efa4 | — | — | 0.702 |
| 9 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.701 |
| 10 | SRR35579843 | — | B | 0.691 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |